Agoracom Blog Home

Archive for the ‘Medical Marijuana Stocks’ Category

Tetra Bio-Pharma $TBP.ca Adds New Marketing Vice-President $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 9:18 AM on Thursday, August 30th, 2018

Logo tetrabiopharma rgb web

  • Announced that Mr. Steeve Neron has joined Tetra Bio-Pharma as Vice-President, Marketing, effective August 20, 2018
  • He will be responsible for all Tetra Bio-Pharma and Tetra Natural Heath marketing activities

ORLEANS, Ontario, Aug. 30, 2018 — Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), is pleased to announce that Mr. Steeve Neron has joined Tetra Bio-Pharma as Vice-President, Marketing, effective August 20, 2018. He will be responsible for all Tetra Bio-Pharma and Tetra Natural Heath marketing activities.

Steeve has more than 32 years’ experience in the pharmaceutical industry with demonstrated success in numerous therapeutic sectors including cardiology, rheumatology, endocrinology, women’s health, asthma/COPD, OTC and dermatology where challenging the reimbursement landscape factored prominently in his role. Prior to joining Tetra Bio-Pharma he occupied a senior marketing position at Bausch Health Canada, formerly Valeant.

Steeve has held various marketing, sales, finance, material management and business development positions and has worked to launch or rejuvenate numerous market leading pharmaceutical brands including Aerius™ (antihistamine), Altace™ (hypertension), Ezetrol™ (cholesterol), Eliquis™ (anti-coagulant), Lodalis™ (cholesterol) and Contrave™ (Obesity).

“I am very proud to add Steeve to our senior management team. His vast experience will enable Tetra to achieve its high standards in executional excellence,” says Richard Giguere Executive Vice-President, Commercial Operations.

“I am very excited to have the opportunity of contributing my pharmaceutical marketing knowledge within the growing cannabinoid-based products sector,” said Steeve Neron. “Tetra has set the bar high from a clinical development standpoint and this is a critical factor to maximize the therapeutic potential of cannabis.”

About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

For more information visit: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including the ability to obtain orphan drug status, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.

Robert (Bob) Bechard
Executive Vice President, Corporate Development and Licensing
514-817-2514
[email protected]

Media Contact
energi PR
Carol Levine
[email protected]
514-288-8500 ext. 225
416-425-9143 ext. 225

Namaste $N.ca $NXTTF Announces Supply Agreement with GTEC Holdings $GTEC.ca $VAPE $VPCO $MCIG $ABCN.ca $ACG.ca $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 8:50 AM on Monday, August 27th, 2018

  • Company has signed a bulk cannabis supply agreement (the “Supply Agreement”) with GTEC Holdings Ltd.
  •  Cannmart Inc. will purchase bulk cannabis flower and oil from GTEC for resale in Cannmart’s online platform

VANCOUVER, Aug. 27, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (TSXV: N) (FRANKFURT: M5BQ) (OTCMKTS: NXTTF) is pleased to announce that the Company has signed a bulk cannabis supply agreement (the “Supply Agreement”) with GTEC Holdings Ltd. (“GTEC”) (TSXV: GTEC) (OTCPK: GGTTF), whereby Namaste’s wholly owned subsidiary and Health Canada’s Access to Cannabis for Medical Purposes (“ACMPR”) late-stage applicant, Cannmart Inc. (“Cannmart”) will purchase bulk cannabis flower and oil from GTEC for resale in Cannmart’s online platform. Cannmart will be Canada’s first ACMPR Licensed Producer (“LP”) with a “sales-only” license, allowing the Company to leverage its e-commerce expertise to become Canada’s leading cannabis online retailer.

This Supply Agreement further demonstrates Namaste’s ability to secure a strong supply chain to help service Namaste’s growing list of patients, and execute on its strategy to create Canada’s largest online retail cannabis platform. GTEC is a Kelowna-based LP which owns and operates several cultivation facilities, and Namaste anticipates GTEC becoming a key supplier for Cannmart’s platform. With the upcoming roll-out of recreational cannabis and with an anticipated short-term national supply shortage, cannabis supply agreements are now more important than ever to Namaste’s long-term strategy. This Supply Agreement further demonstrates Namastes ability to secure a strong supply chain with multiple LP’s.

Namaste’s e-commerce platform and technology will continue to drive innovation that will have a major impact on the way in which patients can access medical cannabis online. Namaste’s goal is to create the most comprehensive user experience possible by personalizing product and strain recommendations through the integration of its AI technology, by providing convenient access to healthcare practitioners, and by driving cannabis sales through Cannmart.

With the recent launch of NamsteMD’s (“NamasteMD.com“) Google Android App, the company expects to see exponential growth having recently reached over 14,000 registered users. The continuous acceleration and strong supply channels have Namaste well-positioned to integrate cannabis sales within its e-commerce platform. The Company has been overwhelmed with support from its LP partners who see Namaste’s vision to become the global leader in online retail for all things cannabis.

Management Commentary

Norton Singhavon, Chairman and CEO of GTEC comments: “GTEC is actively pursuing long-term supply agreements with Licensed Producers whose core competencies are complementary to our own. Accordingly, we are very excited about our partnership with CannMart and Namaste. We believe that GreenTec’s ability to cultivate and market high-quality craft cannabis provides an excellent fit with Cannmart’s packaging and distribution capabilities, and Namaste’s ability to develop a robust network of medical cannabis patients”.

Sean Dollinger, President, and CEO of Namaste comments: “We have been working on securing this Supply Agreement with GTEC for several months and are thrilled to see this come together nicely. GTEC operates multiple facilities and will be launching a new production facility in Kelowna shortly. We’re pleased to have secured another strong supplier for Cannmart.

We’re expecting to receive our sales license very soon and are highly focused on expansion of our patient network and in curating a high-quality offering of cannabis products for our customers. During a time where inventory remains on shortage with many vendors, we are proud to have partners like GTEC who see value in the platform which we’ve created. Thanks to GTEC’s management team for supporting Namaste in its efforts to become Canada’s leading online cannabis retailer and we’re looking forward to a strong partnership together”

About GTEC Holdings Inc.

GTEC was founded in 2017 to capitalize on opportunities in the nascent and rapidly growing legal cannabis industry. GTEC is focused on growing premium quality craft cannabis in purpose-built indoor facilities. The Company also has a number of retail cannabis initiatives in Western Canada.   GTEC currently holds a 100% interest in GreenTec Bio-Pharmaceuticals Corp., Tumbleweed Farms Corp., Falcon Ridge Naturals Ltd., Alberta Craft Cannabis Inc., Grey Bruce Farms Inc., Zenalytic Laboratories Ltd. and Spectre Labs Inc. GTEC is a publicly-traded corporation based in Kelowna, British Columbia. The Company’s shares are listed on the TSX Venture Exchange and OTC Pink Sheets.

About Namaste Technologies Inc.

Namaste Technologies is Your Everything Cannabis Store™. Namaste operates the largest global cannabis e-commerce platform with over 30 websites in 20+ countries under various brands. Namaste’s product offering through its subsidiaries includes vaporizers, glassware, accessories, CBD products, and the company will soon be selling medical cannabis in the Canadian market, subject to approval by Health Canada.

Namaste has developed and acquired innovative technology platforms including NamasteMD.com, Canada’s first Health Canada compliant telemedicine application, and in May 2018 the Company acquired a leading e-commerce AI and Machine Learning Company, Findify AB. Findify uses artificial intelligence algorithms to optimize and personalize a consumer’s on-site buying experience. Namaste is focused on leveraging its cutting-edge technology to enhance the user experience throughout its platforms. Namaste will continue to develop and acquire innovative technologies which will provide value to the Company and to its shareholders as well as to the broader cannabis market.

On behalf of the Board of Directors

“Sean Dollinger”

Chief Executive Officer

Direct: +1 (604) 355-6100

Email: [email protected]

Further information on the Company and its products can be accessed through the links below:

NamasteTechnologies.com

NamasteMD.com

NamasteVapes.ca

Everyonedoesit.ca

FORWARD-LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The TSXV has neither reviewed nor approved the contents of this press release.

View original content with multimedia:http://www.prnewswire.com/news-releases/namaste-announces-supply-agreement-with-gtec-holdings-300702533.html

SOURCE Namaste Technologies Inc.

Namaste $N.ca $NXTTF Announces Approval of NamasteMD Android App and Accelerates Patient Acquisition in Anticipation of Sales License $VAPE $VPCO $MCIG $ABCN.ca $ACG.ca $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 9:03 AM on Friday, August 24th, 2018

  • Announced that the Company has received official approval of the latest version of its NamasteMD cannabis telemedicine App for Google Android devices,
  • Live in the Google Play store as of 8 AM EST August 23rd, 2018

VANCOUVER, Aug. 24, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (TSXV: N) (FRANKFURT: M5BQ) (OTCMKTS: NXTTF) is pleased to announce that the Company has received official approval of the latest version of its NamasteMD (“NamasteMD.com“) cannabis telemedicine App for Google Android devices, which is live in the Google Play store as of 8 AM EST August 23rd, 2018. Approximately 50% of mobile phone users in Canada use Android devices. With the new launch of the apps on both iOS and Android platforms, NamasteMD can now facilitate online patient consultations, free of charge, within 15 minutes from sign-up on the App. The Company anticipates launching real-time consultations through NamasteMD within the next 10 days. Further to the Company’s Aug 22nd news release, NamasteMD has achieved over 14,000 registered users, representing a 130% increase over a 2-month period. The Company anticipates significant acceleration in conversion rates with additional exposure through the Google Play store.

Namaste has developed Canada’s first fully-compliant medical cannabis patient portal, available on iPhone or Android devices, which allows Namaste to acquire patients faster and at a lower cost in comparison with other Licensed Producers. Patients acquired through NamasteMD have access to purchase medical cannabis through Namaste’s cultivation partners (“Licensed Producers). Under the terms of various Educational Service Agreements (“Service Agreements”), Namaste collects between 15-20% of the gross revenue derived from patient purchasing through referrals to Licensed Producers under NamasteMD. Namaste is presently partnered with over 10 Licensed Producers.

With Namaste’s medical cannabis “sales-only” license imminent, the Company anticipates a sharp increased revenue and margin with Cannmart booking full revenue amounts from patient ordering and the Company will aim to maintain a minimum of a 50% gross margin on cannabis products sold directly on its website.

Namaste operates over 30 e-commerce sites across the globe with over 1.5 Million customers. Integration of cannabis and consumable sales including CBD products into Namaste’s platform will propel the Company to become a global leader in the online retail of all things cannabis. The Company will launch the same strategy in leveraging its consumer databases along with its innovative technology platforms to expand NamasteMD and Cannmart’s model into international markets where Namaste maintains significant market share.

Management Commentary

Sean Dollinger, President, and CEO of Namaste comments: “We’re very pleased to announce the launch of NamasteMD in the Google Play Store. We have been overwhelmed by the acceleration rate of our registered users and anticipate seeing even faster growth having now received approval from Google. With approximately 50% of mobile phone users operating on Google Android devices, we are expecting to see patient numbers accelerate even quicker than we have experienced so far. NamasteMD is a key component of our strategy in developing Canada’s largest medical cannabis patient database and in launching cannabis sales in Canada and abroad. While the process of acquiring a medical cannabis prescription and onboarding with a Licensed Producer typically can take several days or weeks, Namaste will offer a fully-integrated platform for new patients to consult with a nurse practitioner and immediately be connected with Cannmart to order their product. We believe in bringing value to our patients through technological innovation and aim to set the highest standard for patient care going forward.”

About Namaste Technologies Inc.

Namaste Technologies is Your Everything Cannabis Store™. Namaste operates the largest global cannabis e-commerce platform with over 30 websites in 20+ countries under various brands. Namaste’s product offering through its subsidiaries includes vaporizers, glassware, accessories, CBD products, and the company will soon be selling medical cannabis in the Canadian market, subject to approval by Health Canada.

Namaste has developed and acquired innovative technology platforms including NamasteMD.com, Canada’s first Health Canada compliant telemedicine application, and in May 2018 the Company acquired a leading e-commerce AI and Machine Learning Company, Findify AB. Findify uses artificial intelligence algorithms to optimize and personalize a consumer’s on-site buying experience. Namaste is focused on leveraging its cutting-edge technology to enhance the user experience throughout its platforms. Namaste will continue to develop and acquire innovative technologies which will provide value to the Company and to its shareholders as well as to the broader cannabis market.

On behalf of the Board of Directors

“Sean Dollinger”

Chief Executive Officer

Direct: +1 (786) 389 9771

Email: [email protected]

Further information on the Company and its products can be accessed through the links below:

NamasteTechnologies.com

NamasteMD.com

NamasteVapes.ca

Everyonedoesit.ca

FORWARD-LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The TSXV has neither reviewed nor approved the contents of this press release.

View original content with multimedia:http://www.prnewswire.com/news-releases/namaste-announces-approval-of-namastemd-android-app-and-accelerates-patient-acquisition-in-anticipation-of-sales-license-300701963.html

$APPB Applied BioSciences Eagerly Awaiting Hightimes IPO $HTIM

Posted by AGORACOM at 1:26 PM on Wednesday, August 1st, 2018

https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564626/hub/APPB_logo.png

 

  • Applied BioSciences early stage investment in Hightimes Magazine is valued at approximately $1.75 Million at assumed IPO Pricing of $11.00
  • HTIM anticipates a total raise of $50 million
  • Former Mexican President Vicente Fox set to join High Times Board of Directors
  • Experts predict cannabis industry will grow to $20 Billion by 2020
  • Applied BioSciences is uniquely poised to recieve a return on investment.

Applied BioSciences Corp. (www.appliedbiocorp.com), is a diversified company focused on multiple areas of the medical, bioceutical and pet health industry. As a leading company in the CBD and Pet health space, the company is currently shipping to the majority of US states as well as to 5 International countries. The company is focused on select investment, consumer brands, and partnership opportunities in the recreational, health and wellness, nutraceutical, and media industries.

The company has several strategic partnerships and investments currently in place and is actively pursuing additional partnerships and strategic growth opportunities.

Contact

Email: [email protected] or [email protected]

To be added to the Applied BioSciences email distribution list, please email [email protected] with APPB in the subject line.

Official Website: www.appliedbiocorp.com

Brands:

www.remedishop.com
www.therpet.com

Follow us:

Facebook @remedicbd & @therpetcbd
Instagram @remedicbd & @therpet
Twitter @remedishop & @therpet

FULL DISCLOSURE: AppliedBiosciences is an advertising client of AGORA Internet Relations Corp.

FEATURE: Applied Biosciences – Poised to Succeed in CBD Market $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM at 12:43 PM on Tuesday, July 31st, 2018

        

  • Consumer company with Multiple CBD Brands focused on Consumer, Pet, Female and Health and Wellness
  • Building brand with a scalable process and operation
  • Commenced sales of its hemp-derived CBD products on LeafLink’s industry-leading B2B e-commerce platform
  • Launched CBD product line under the Remedi CBD brand
  • Products will be sold on Remedi’s new website (www.remedishop.com) and in select locations in the U.S.
  • Launched CBD product line under TherPet brand (https://therpet.com/)
  • Currently shipping to the majority of US states and Internationally to 5 countries
  • Several strategic partnerships and investments currently in place
  • Partners include: High Times & GemmaCert

Key Market Drivers

     Increasing Momentum Towards Legalization

  • Especially related to medical -use Cannabis
  • Cannabis is legal in 29 states and the District of Columbia in some form ( or decriminalized )
  • International Opportunities: * Cannabis is now trading globally, with Canadian grown Medical cannabis being exported to Germany, Croatia, New Zealand, Brazil and Chile. The Dutch are sending shipments of medical cannabis to Italy, Germany and Finland.   

     Shifting Public Opinion

  • Belief that the growth of the regulated cannabis industry has been fueled by changing public attitudes in the United States. A 2015 poll by Harris found 81% of Americans support the legalization of cannabis for medical use. Driven in part by this shift in public opinion.       

                        

About Applied BioSciences Corp.

Applied BioSciences Corp. (www.appliedbiocorp.com), is a diversified company focused on multiple areas of the medical, bioceutical and pet health industry. As a leading company in the CBD and Pet health space, the company is currently shipping to the majority of US states as well as to 5 International countries. The company is focused on select investment, consumer brands, and partnership opportunities in the recreational, health and wellness, nutraceutical, and media industries.

The company has several strategic partnerships and investments currently in place and is actively pursuing additional partnerships and strategic growth opportunities.

Contact

Email: [email protected] or [email protected]

To be added to the Applied BioSciences email distribution list, please email [email protected] with APPB in the subject line.

Official Website: www.appliedbiocorp.com

Brands:

www.remedishop.com
www.therpet.com

Follow us:

Facebook @remedicbd & @therpetcbd
Instagram @remedicbd & @therpet
Twitter @remedishop & @therpet

Tetra Bio-Pharma $TPB.ca Confirms Meetings With FDA $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:33 AM on Thursday, July 26th, 2018

Logo tetrabiopharma rgb web

  • Announced that it received two meeting granted letters from the United States Food and Drug Administration (FDA), for Type B and C meetings,
    • discuss requirements for obtaining marketing approval under the 505(b)(2) regulatory pathway for its dronabinol AdVersa™ mucoadhesive product, PPP002. 

Type B & C Meetings Move TBP Closer to Market Approval

ORLEANS, Ontario, July 26, 2018 (GLOBE NEWSWIRE) — Tetra Bio-Pharma Inc., (“Tetra” or the “Company”) a leader in cannabinoid-based drug discovery and development (TSX VENTURE:TBP) (OTCQB:TBPMF) today announced that it received two meeting granted letters from the United States Food and Drug Administration (FDA), for Type B and C meetings, to discuss requirements for obtaining marketing approval under the 505(b)(2) regulatory pathway for its dronabinol AdVersa mucoadhesive product, PPP002.

Tetra, along with its partner IntelGenx Corp, is developing this product in the USA under the accelerated 505(b)(2) pathway for chemotherapy-induced nausea and vomiting and anorexia and weight loss in people with AIDS (the same indications that have already been approved for Marinol®).  The 505(b)(2) speciality Contract Research Organization, Camargo, is guiding the regulatory submissions to the FDA. The corporation is also developing PPP002 in Canada as an adjunct therapy for opioid reduction in patients with chronic pain.

According to the International Agency for Research on Cancer1, the global chemotherapy-induced nausea and vomiting (CINV) market will reach a valuation of US$1.88 bn by 2020, an increase from its 2013 valuation of US$1.28 bn. Based on the expected improved safety profile of delayed release dronabinol, Tetra expects that AdVersa™ can gain significant market share within three (3) years of its launch in the USA.

Reducing Opioid Use
The opioid crisis is serious and growing throughout North America. Tetra’s rich cannabinoid-derived product pipeline has the potential to play a significant role in opioid sparing, thus addressing a societal issue of critical proportion. The Corporations research and development team is exploring the application of cannabis for other painful therapeutic indications such as the multi-billion-dollar fibromyalgia market, which would vastly increase the potential market as well shareholder value.

“Confirmation of these two meetings with FDA marks an important milestone in gaining accelerated marketing approval in the USA for PPP002. Tetra will use the information provided by the FDA in these meetings to finalize preparation of the NDA file,” said Dr. Guy Chamberland, Interim CEO and Chief Scientific Officer of Tetra Bio-Pharma.

Alongside these meetings, Tetra and IntelGenx are working together to finalize the Clinical Trial Applications (CTAs) for the upcoming comparative pharmacokinetic and opioid sparing trials, to support development for the 505(b)(2) and opioid sparing indications, respectively. Tetra expects to file these CTAs with Health Canada in Q3 2018.

About IntelGenx
Established in 2003, IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform. IntelGenx’s highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx’s state-of-the-art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to its clients. More information about the company can be found at www.intelgenx.com

About Camargo
Camargo Pharmaceutical Services is the global development and commercialization partner with a proven ability to help bring life-changing therapies to the market faster and more cost-effectively. Founded in 2003, the company offers a full portfolio of pharmaceutical services from concept through commercialization to improve medicines. Camargo has emerged as one of the recognized experts and industry leaders utilizing the FDA 505(b)(2) approval pathway. The company is passionate about the client’s success and the differences they can make in the lives of others. Camargo’s global reach and client base extends to more than 25 countries.  Camargo is headquartered in Cincinnati, Ohio. For more about Camargo Pharmaceutical Services, visit http://camargopharma.com.

About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies. More information at: www.tetrabiopharma.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including the success of this or any other clinical trial, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.:

Robert (Bob) Bechard
Executive Vice President, Corporate Development and Licensing
514-817-2514

For investors information, please contact:
[email protected]
(438) 504-5784
Media Contact:
energi PR
Lana Power
416-425-9143 ext. 201
[email protected]

Namaste $N.ca $NXTTF Announces New AI-Driven #Cannabis Mobile Strain Recommendation App Uppy Cannabis Journal $VAPE $VPCO $MCIG $ABCN.ca $ACG.ca $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 8:35 AM on Thursday, July 19th, 2018

  • Announced that the company has submitted applications to the Apple and Google Play stores in order to launch its latest mobile application, Uppy Cannabis Journal
  • Uppy Cannabis Journal is the first artificial intelligence (“AI”) driven medical cannabis app, which is designed to collect direct feedback on cannabis strains and over time provide strain and cannabis hardware recommendations

VANCOUVER, July 19, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (TSXV: N) (FRANKFURT: M5BQ) (OTCMKTS: NXTTF) is pleased to announce that the company has submitted applications to the Apple and Google Play stores in order to launch its latest mobile application, Uppy Cannabis Journal. Uppy Cannabis Journal is the first artificial intelligence (“AI”) driven medical cannabis app, which is designed to collect direct feedback on cannabis strains and over time provide strain and cannabis hardware recommendations. Namaste has implemented its AI technology through the Company’s wholly owned subsidiary Findify AB (“Findify” or “Findify.io”) and has fed over 2 million pieces of unique data to the platform which forms the base on which the algorithm will evolve and adapt itself to better understand the effects of cannabis strains in relation to treatment of many symptoms.

Through Uppy Cannabis Journal, Namaste’s customers and medical cannabis patients will have the access to journal their experiences using various strains of cannabis to treat their symptoms. The data collected over time will allow the algorithm to characterize the way different strains of cannabis benefit different people suffering from different symptoms. The goal of the Uppy Cannabis Journal is to develop a shopping experience whereby patients are provided with the best possible strain recommendations personalized for their needs, based on factual data collected through Namaste’s network of e-commerce sites, combined with user-feedback and AI technology.

Namaste will leverage its database of over 1.5 million consumers on a global scale to collect as much patient and strain data as possible. The implementation of AI technology in strain recommendations opens the door to a deeper level of understanding in how cannabis and different strain profiles treat medical symptoms. Namaste is well-positioned with its expansive international database of cannabis consumers to develop the Uppy Cannabis Journal app to a platform that ultimately will serve to benefit cannabis patients on a global scale. Once the app is approved by Apple and Google, Namaste will begin a marketing program to drive traffic from its own sites to Uppy Cannabis Journal and to attract new users through various digital marketing strategies.

The Company remains focused on developing innovative technologies like Uppy Cannabis Journal and NamasteMD, that provide value to Namaste and its shareholders but also bring great value to the industry, the Company’s peers and patients across the globe. Namaste is keen to differentiate itself in an industry focused on cultivation, as a leader in cannabis technology. Uppy Cannabis Journal provides Namaste with a tool to leverage its e-commerce platform to collect valuable data. Furthermore, the integration of Findify’s AI technology with Uppy Cannabis Journal is a ground-breaking event that will fuel a deeper level of understanding for cannabis patients.

Real-world applications of AI are best suited for implementation in e-commerce, healthcare and logistics environments. With Namaste’s large base of online traffic, the Company can collect substantial data in relation to cannabis patients and strains that will be leveraged using the most innovative AI technology in the market. Namaste will be the first company to dive deep into this exciting area of the industry and in enhancing the user experience for medical patients by providing more relevant recommendations based on the specific needs of individual patient’s. The Company will be able to immediately monetize the data collected by integrating Uppy Cannabis Journal with its e-commerce platform and its upcoming medical cannabis “sales-only” license through the Company’s wholly owned subsidiary and Access to Cannabis for Medical Purposes (“ACMPR”) applicant, Cannmart Inc.

Management Commentary

Chad Agate, CTO of Namaste comments; “The coming launch of Uppy Cannabis Journal represents the next phase of our integration of the Findify AI team into the Namaste platform core – applying machine learning models to help our users have the best cannabis experience in the world. I’m very proud of our world-class team of engineers and designers. We are spending time looking at how we are using technology today during interactions with our customers and focused on how the value of that moment could be increased. For the dedicated Namaste team, machine learning and AI is not about providing novel tools anymore, it is about creating a new type of organization. Our role model is Amazon, which has been able to apply its formula of automation, innovation and data-driven everything to solve seemingly unrelated business issues.”

Sean Dollinger, President and CEO of Namaste comments; “This is a very exciting moment for Namaste. Our acquisition of Findify will now show true value to the cannabis industry. Imagine having a platform which has been developed with millions of data points and that uses machine learning algorithms to gain a better understanding of the complex relationships between cannabis strain profiles and treating patient symptoms. We believe that that the Uppy platform will provide better strain recommendations for patients based on actual data that we can collect and analyze using some of the most advanced AI technology on the market today. Each cannabis strain has its own unique profile of cannabinoids and terpenes which define the characteristics of the particular strain and how it impacts patients on an individual basis.

Namaste is leading the industry in developing the most valuable technology platforms and in collecting data on a global scale that serves the Company, its consumers, patients and shareholders. I truly believe that this is something we should be proud of as a company and I feel confident Uppy will help better educate patients from across the globe by assisting them in making more informed decisions. We believe our users will find incredible value in this revolutionary educational tool which we will believe is essential in building patient trust and loyalty. Our ability to allow our patients real-time feedback is very exciting, as we once again lead the industry in new initiatives designed with a “patient first mentality” in mind. This was the last step needed in Namaste’s sales funnel and in creating a personalized consumer experience. I’d like to thank our Technology team at Namaste and our incredible CTO Chad Agate who continues to create and innovate incredible technology that will provide long term value to the Company.”

About Namaste Technologies Inc.

Namaste Technologies is Your Everything Cannabis Store™. Namaste operates the largest global cannabis e-commerce platform with over 30 websites in 20+ countries under various brands. Namaste’s product offering through its subsidiaries includes vaporizers, glassware, accessories, CBD products, and the company will soon be selling medical cannabis in the Canadian market, subject to approval by Health Canada.

Namaste has developed and acquired innovative technology platforms including NamasteMD.com, Canada’s first Health Canada compliant telemedicine application, and in May 2018 the Company acquired a leading e-commerce AI and Machine Learning Company, Findify AB. Findify uses artificial intelligence algorithms to optimize and personalize a consumer’s on-site buying experience. Namaste is focused on leveraging its cutting-edge technology to enhance the user experience throughout its platforms. Namaste will continue to develop and acquire innovative technologies which will provide value to the Company and to its shareholders as well as to the broader cannabis market.

On behalf of the Board of Directors

“Sean Dollinger”

Chief Executive Officer

Direct: +1 (786) 389 9771

Email: [email protected]

Further information on the Company and its products can be accessed through the links below:

NamasteTechnologies.com

NamasteMD.com

NamasteVapes.ca

Everyonedoesit.ca

FORWARD-LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The TSXV has neither reviewed nor approved the contents of this press

SOURCE Namaste Technologies Inc.

Namaste $N.ca $NXTTF Signs Services Agreement with Indigenous Canadian Medical Dispensaries (IcMD) to Provide Patient Consultations to Over 1.5 Million Indigenous Community Members Exclusively through NamasteMD $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 8:45 AM on Tuesday, July 3rd, 2018

  • Company has signed an exclusive Software Services Agreement (the “Agreement”) with Indigenous Canadian Medical Dispensaries Inc
  • Partnering with IcMD to provide all Indigenous communities across Canada (representing a population of over 1.5 million people) with free access to the Company’s revolutionary telemedicine application and online patient portal, NamasteMD

VANCOUVER, July 3, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (TSXV: N)(FRA: M5BQ)(OTCMKTS: NXTTF) is pleased to announce the Company has signed an exclusive Software Services Agreement (the “Agreement”) with Indigenous Canadian Medical Dispensaries Inc. (“IcMD” or “IcMD.ca”), whereby Namaste is partnering with IcMD to provide all Indigenous communities across Canada (representing a population of over 1.5 million people) with free access to the Company’s revolutionary telemedicine application and online patient portal, NamasteMD. The Company anticipates that this Agreement will drive further patient growth in Namaste achieving its target of acquiring over 50,000 medical cannabis patients by the end of 2018 and 200,000 by the end of 2019.

Under the terms of the Agreement, NamasteMD will provide IcMD with exclusive access to its online platform for Indigenous people across Canada, via both desktop and mobile phone platforms, on both Apple iOS and Android devices. In turn, IcMD has agreed to offer NamasteMD exclusivity for all its online patient consultations across Canada. As part of the Agreement, Namaste will use a unique code for IcMD to track patient acquisition from IcMD’s channels, and will offer medical cannabis, pharmaceutical products, as well as medical devices.

This Agreement represents a significant milestone, as Namaste and IcMD collaborate in providing Indigenous communities across Canada with the right to access medical cannabis. This will be accomplished by offering all community members with free consultations, whereby patients have instant access to doctors or nurse practitioners. Namaste and IcMD believe they can help bridge the gap for Indigenous communities across Canada who are suffering from an overwhelming lack of access to quality healthcare services. Through a platform powered by NamasteMD’s technology, IcMD plans to potentially provide healthcare access to over 1.5 million Indigenous peoples, many of whom currently reside in remote or rural areas, and have little to no access to comprehensive clinic services.

This Agreement embodies Namaste and IcMD’s belief that all Indigenous people across Canada, whether in urban environments or rural communities, should have proper access to healthcare practitioners and medical cannabis.  IcMD’s management team is committed to supporting Indigenous communities and believes NamasteMD will serve as a powerful tool to enhance the lives of many members. Both Namaste and IcMD view this partnership as an incredible opportunity to become leaders in the Indigenous medical cannabis and direct healthcare space by providing people with safe and reliable access to healthcare in their hands.

Namaste views this opportunity as potentially one of the most significant initiatives it has embarked on to date. Once deployed, Namaste believes its platform has the ability to have a significant social impact on Indigenous communities across Canada. Namaste and IcMD are also confident this technology has the ability to catch the attention of Indigenous leaders on a global scale once its effects are observed within the Canadian market. This represents a unique opportunity for both parties to come together and work with Indigenous leaders across the country in helping drive social reform.

At a time when political leaders at all levels of government have acknowledged an impending opioid epidemic, it would appear that there is no better time to implement better access to healthcare. By making it easier and more affordable to access doctors and nurse practitioners, it is believed that this will allow Indigenous members, whose communities have been some of the hardest hit, the ability to make more informed choices under the guidance of a trained professional.

The fact that the Indigenous market and its people have consistently been left out of equal access to healthcare is something Namaste and IcMD are extremely excited to change. Starting with nationwide access to medical cannabis and moving forward to health consultations and treatment plans Namaste & IcMD will truly be putting healthcare in the hands of the people.

Namaste’s wholly owned subsidiary, Cannmart Inc. (“Cannmart”) is a late-stage applicant for a medical cannabis “sales-only” license that will serve to provide a diverse selection of cannabis from preferred cultivation partners and will be integrated with IcMD’s platform through NamasteMD upon receipt of its sales license.

IcMD and Namaste are excited to attend and launch IcMD at the Assembly of First Nation’s 39th General Assembly in Vancouver, BC July 23 to 26, 2018. Namaste and IcMD will be highlighted in a booth at the AFN Circle of Trade. The AFN Circle of Trade provides the opportunity to meet, network and showcase products to over 4,500 key decision makers and influencers from a growing market within the First Nations communities across Canada.

The Assembly of First Nations (AFN) is a national advocacy organization representing First Nation citizens in Canada, which includes more than 900,000 people living in 634 First Nation communities and in cities and towns across the country. http://www.afn.ca/about-afn/

Namaste is pleased to be hosting a special edition Namaste420 Youtube live-stream at 9:00 AM EST on July 3rd, 2018 to discuss the Agreement with IcMD and answer questions. To join the stream please visit the link below;

https://www.youtube.com/watch?v=SOJb-uO-OXg

Management Commentary

Christopher Henry, CEO of IcMD comments: “As a proud member of the MMF I have been consistently involved in Indigenous employment and advancement to towards complete self-sufficiency. For the past 25 years, I have worked closely with and in Indigenous communities across Canada. During that time, I have personally seen the lack of access to almost every service most Canadians take for granted every day. By partnering with Namaste Technologies and NamasteMD we are able to gain access to technology that would allow us to realize our dream of putting healthcare in the hands of the people. This has the potential to change how we provide healthcare to Indigenous communities across Canada and bring them one more step to equality with all Canadians.”

Christopher Henry is a member of the Manitoba Metis Federation and co-owner of WorkingWarriors.ca a national Indigenous Engagement and Employment Company.

Michael Birch, President, and COO of IcMD comments: “I grew up in Garden Hill First Nation. A fly in remote community in Northern Manitoba with over 3000 residents. We didn’t have access to a doctor or nurse or even a healthcare facility at times. To be able to put access to reliable secure healthcare in the hands of our people is a dream I didn’t think would ever happen in my lifetime. By partnering with Namaste and NamasteMD we will finally be able to give all Indigenous people, regardless of location, access to a more equal standard of care.”

Michael Birch is an entrepreneur originally from Garden Hill First Nation. He is owner & President of MBE a Facility Management and Logistics Company for Indigenous communities.

Sean Dollinger, President and CEO of Namaste comments: “We are beyond honored to have partnered with IcMD and their management team who exemplify the nature of Namaste and our core values. We truly believe that our technology will improve the health and well-being of hundreds of thousands of people in Indigenous communities across Canada. The level of accessibility to high-quality healthcare that we will be able to offer has the ability to create a significant social impact to all Indigenous communities. We are proud to be partnered with IcMD’s management team who are deeply committed to this cause.

This Agreement is just the start of what we feel will evolve into a long-term relationship and success in bringing value to the lives of many Indigenous people. While the legalization of recreational cannabis may not be accessible to community members across Canada, Namaste will serve to provide convenient access to medical cannabis in remote areas not yet served by the recreational market.

For IcMD to select Namaste among hundreds of ACMPR Licensed Producers in Canada, speaks volumes as to the value in our technology and we feel privileged to embark on this new and exciting initiative for the betterment of all Indigenous communities and its members. We’d like to thank IcMD’s team, Christopher Henry and Michael Birch for their support and hard work in putting together this exciting partnership.

We’re also pleased to announce the submission of the TSX Venture Form 5G at the close of the market on Friday, June 29th, 2018, and we anticipate commencing our Normal Course Issuer Bid (“NCIB”), whereby the Company will purchase up to 25,308,136 of its common shares, or 8.9% of the “Public Float” (as such term is defined in the TSX-V Corporation Finance Manual).”

About Indigenous Cannabis Medical Dispensaries Inc.

IcMD’s goal is to put reliable and accessible healthcare in the hands of Indigenous people. By working with our relationships created over a lifetime of work in the Indigenous community IcMD will bring medical cannabis to every region of Canada. We believe that the over prescription of pharmaceuticals to our people has had a negative effect on our communities. By offering a natural solution to many common conditions we believe will we be more able to return to our traditional roots. Moving towards health consultations and treatment plans will eventually see IcMD as the nationwide leader in direct Indigenous healthcare equality.

About Namaste Technologies Inc.

Namaste Technologies is a global leader in the sale of medical cannabis consumption devices. Namaste has nine offices with multiple distribution centers around the globe and operates over 30 websites under various brands. Namaste has developed innovative technology platforms including NamasteMD.com, Canada’s first ACMPR compliant telemedicine application. The company is focused on patient acquisition through NamasteMD and intends on building Canada’s largest database of medical cannabis patients. The company’s subsidiary, CannMart Inc. is an ACMPR Licensed Producer pending receipt of   a “sales-only” license, whereby the company will offer a large variety of medical cannabis sourced from domestic and international producers. Namaste will continue to develop and acquire innovative technologies which will provide value to the Company and to its shareholders as well as to the broader cannabis market.

On behalf of the Board of Directors

“Sean Dollinger”

Chief Executive Officer

Direct: +1 (786) 389 9771

Email: [email protected]

Further information on the Company and its products can be accessed through the links below:

NamasteTechnologies.com

NamasteMD.com

NamasteVapes.ca

Everyonedoesit.ca

FORWARD-LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Neither the TSX Venture Exchange nor its market regulator has reviewed or approved the contents of this press release.

SOURCE Namaste Technologies Inc.

View original content with multimedia: http://www.newswire.ca/en/releases/archive/July2018/03/c4242.html

Namaste $N.ca $NXTTF Announces Intention to Commence a Normal Course Issuer Bid to Repurchase Up to 10% of its Public Float and Provides a Corporate Update Including Incoming CFO, New Board Director and Consultants $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 8:48 AM on Thursday, June 28th, 2018

  • Subject to regulatory approval, it intends to commence a normal course issuer bid 
  • The Company intends to purchase up to 25,308,136 common shares, representing approximately 8.9% of the Company’s issued and outstanding common shares and 10% of the Company’s “public float”

VANCOUVER, June 28, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (TSXV: N)(FRA: M5BQ)(OTCMKTS: NXTTF) is pleased to announce that, subject to regulatory approval, it intends to commence a normal course issuer bid (“NCIB”). The Company intends to purchase up to 25,308,136 common shares, representing approximately 8.9% of the Company’s issued and outstanding common shares and 10% of the Company’s “public float” (as such term is defined in the TSX-V Corporation Finance Manual).

The Company is in the process of appointing Canaccord Genuity Inc. as its broker to conduct the NCIB on its behalf. The NCIB will commence three business days following the TSX-V’s acceptance of the Company’s Notice of Intention to commence the NCIB.

All purchases will be made through the facilities of the TSX-V at market prices and otherwise in accordance with the rules and policies of the TSX-V. All common shares acquired by the Company under the NCIB are being purchased for cancellation.

Namaste’s board of directors believes that, from time to time, the market price of the common shares does not adequately reflect the Company’s underlying value and future prospects and that, at such times, the purchase of the common shares represents an appropriate use of the Company’s financial resources and will enhance shareholder value.

In addition to the NCIB, the Company is pleased to announce the appointment of Kenneth Ngo as the Company’s CFO and the appointment of Fern Glowinsky, president of Merrco Payments Inc. (“Merrco”) to the Company’s board of directors. Namaste has also engaged advisory consultants including Tim Henley and Dr. Paul Neider (DVM) who are focused on launching CBD production for both human and pet consumption in Namaste’s international markets. Additionally, the Company’s board of directors has approved new stock options grants in accordance with the Company’s stock option plan.

CFO Appointment

The Company is also pleased to announce the appointment of Kenneth Ngo as Namaste’s CFO. Kenneth Ngo joined Namaste Technologies Inc. as a corporate controller in April 2018.  He has more than 20 years of experience in finance and has held positions of increasing responsibility in a number of US and Canadian publicly traded companies.  He received his Chartered Accountant designation while working for Deloitte LLP.  Mr. Ngo is a graduate of Simon Fraser University in British Columbia, with a Bachelor of Business Administration degree. He is a member of the Chartered Professional Accountants of Ontario and a U.S. Certified Public Accountant in the state of Colorado.

Mr. Ngo, Namaste CFO comments: “I’m thrilled to being part of an exciting journey. Namaste is a true visionary of technology platforms that is well positioned for significant growth.”

Subsequently, Mr. Philip Van der Berg has submitted his resignation as Namaste CFO and the Company would like to take the opportunity to thank him for his service and wish him best of luck on his future endeavors.

Board Appointment

The Company is pleased to announce the appointment of Fern Glowinsky, CEO of Merrco to its board of directors. Namaste has been a client of Merrco for several years and is proud to have their CEO join the board. Fern Glowinsky joined Merrco in March 2018 following its acquisition of Payfirma Corporation. Merrco and Payfirma are committed to helping established and emerging businesses thrive through access to payments technology. Ms. Glowinsky has extensive payments sector experience, spending 15 years as a senior executive at Moneris, most recently as COO with accountability for enterprise operations, passionately focused on transforming customer experience. In 2016 Ms. Glowinsky joined Cliffside Capital as CEO and Director, managing its investments in the alternative lending sector. Ms. Glowinsky is a graduate of the joint MBA/JD program at Schulich School of Business and Osgoode Hall Law School and holds the ICD.D designation.

Fern Glowinsky, comments: “With Merrco’s dedication to enabling payments in the cannabis sector, I’m extremely excited to be joining Namaste’s board and partnering with Sean, his team and the rest of the board as Namaste continues its mission of innovating cannabis technology solutions globally, while delivering a better user experience.”

Advisory Consultants

Subject to TSX-V approval, Namaste is planning on launching the sale of CBD products in international markets, particularly in the under-serviced markets in the UK and EU and has been working hard to develop new sales channels. As such, Namaste has engaged two consultants, Tim Henley and Dr. Paul Neider who provide valuable resources that will have a direct impact on the success of such endeavors. These two appointments will help Namaste in launching CBD products for both human consumption and for animal applications, as Dr. Neider is a doctor of veterinary medicine and supporter of CBD use to support the well-being of pets and animals.

Tim Henley has spent the last 3 years researching and studying the Cannabinoid space and trends. His research in CBD (Cannabidiol) lead him to become a Director of the UK’s Cannabis Trades Association.  Tim was instrumental in helping organize the early days of the association and its membership. He subsequently stood down to pursue a more radical approach to economic development and cannabis reform. Tim has been actively engaged in working with Namaste to assess the regulatory requirements for the sale of CBD products in the UK and has provided advisory services to both Namaste and its partners in the context of packaging and marketing of CBD products. Tim’s role with Namaste outside of his consultancy will be procuring the highest quality CBD products for the Company’s e-commerce marketplace.

Tim Henley, Namaste’s New Products Manager comments: “I came across Namaste when developing my business. I wanted to sell vaporizers and found Namaste to be a really easy modern company to deal with and set up my own company, Cannablyss Ltd.  I would often talk to Kory Zelickson, co-founder, as I placed my wholesale orders. I am an evangelist for 21st Century Cannabis and its potential to help humanity fix so many of the ills of modern society. Be it the revolution in our understanding of the Endocannabinoid system and how this affects our bodies in so many ways. We need to nourish our minds and bodies with Phyto cannabinoids not pharmaceuticals. The changes I have seen in the industry are nothing compared to what is coming. Namaste is helping to create the future and it’s the most exciting and dynamic company I have ever worked for. Namaste is going to change the world building a sustainable future!!”

Paul Neider is an accomplished veterinarian and serial entrepreneur.  Being the founder of three veterinary hospitals, three other companies, shows Paul’s creativity and ability to diversify into various fields. He is passionate about helping animals (humans too) which carries through to his activities with Namaste.  He will work at a task until perfection and never stops learning. Dedicated, enthusiastic and fun to be around, living with four dogs reminds him to just chase a ball once in a while!

Paul Neider, DVM comments: “The team at Namaste is one of the most innovative and passionate group of entrepreneurs I’ve met in a long time. By joining them I will help expand the company into the very large veterinary/pets market.”

Stock Option Grant

Subject to the terms of the Company’s Stock Option Plan, Namaste’s board of directors has approved the issuance of 2,515,000 options to a number of employees and consultants of the Company. All options are exercisable at a price of $1.32 per common shares for a period of five years. The options will vest in quarterly instalments over a two-year period.

Management Commentary

Sean Dollinger, President and CEO of Namaste comments: “We’re very pleased to announce strengthen Namaste’s corporate governance team by announcing the appointment of Kenneth Ngo as our new CFO and Fern Glowinsky to our board of directors. Both Kenneth and Fern will provide great value to the company in their respective roles. We believe that Namaste is remains in the infancy stage of our development as a technological leader in the global cannabis industry and as such are pleased to announce our intentions to commence a NCIB to buy back and cancel up 10% of the Company’s “public float”. Furthermore, we’re very pleased to bring on Tim Henley and Paul Neider to lead the launch of high-quality CBD products in our platform for both human and animal use. CBD products have been proven effective in treating many conditions and in improving overall health and well-being.

We’d like to take the opportunity to thank everyone for their support and to welcome new members to the team. We are very excited about the future of the Company and look forward to many milestones to come. Namaste is constantly evolving and adapting to the changing landscape of this exciting industry that we are very proud to be a part of.”

About Namaste Technologies Inc.

Namaste Technologies is a global leader in the sale of medical cannabis consumption devices. Namaste has nine offices with multiple distribution centers around the globe and operates over 30 websites under various brands. Namaste has developed innovative technology platforms including NamasteMD.com, Canada’s first ACMPR compliant telemedicine application. The company is focused on patient acquisition through NamasteMD and intends on building Canada’s largest database of medical cannabis patients. The company’s subsidiary, CannMart Inc. is an ACMPR Licensed Producer pending receipt of   a “sales-only” license, whereby the company will offer a large variety of medical cannabis sourced from domestic and international producers. Namaste will continue to develop and acquire innovative technologies which will provide value to the Company and to its shareholders as well as to the broader cannabis market.

On behalf of the Board of Directors

“Sean Dollinger”
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: [email protected]

Further information on the Company and its products can be accessed through the links below:

NamasteTechnologies.com
NamasteMD.com
NamasteVapes.ca
Everyonedoesit.ca

FORWARD-LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Neither the TSX Venture Exchange nor its market regulator has reviewed or approved the contents of this press release.

SOURCE Namaste Technologies Inc.

View original content with multimedia: http://www.newswire.ca/en/releases/archive/June2018/28/c3500.html

 

Sean Dollinger, Chief Executive Officer, Direct: +1 (786) 389 9771, Email: [email protected] CNW Group 2018

Namaste $N.ca $NXTTF signs Master Services Agreement with Australian-based YPB to Provide consumer confidence solutions to its customers $ATT.ca $ABCN.ca $ACG.ca $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 8:36 AM on Wednesday, June 27th, 2018

  • Announced signing of a Master Services Agreement with YPB Group Ltd. (“YPB”)(ASX: YPB), an Australian based product verification and customer engagement company
  • Namaste plans to introduce YPB’s solutions across its network of manufacturers and to Canadian Licensed Producers to bring certainty of authenticity and supply chain transparency to the entire legal cannabis industry globally

VANCOUVER, June 27, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (TSXV: N)(FRA: M5BQ)(OTCMKTS: NXTTF) is pleased to announce signing of a Master Services Agreement (the “Agreement”) with YPB Group Ltd. (“YPB”)(ASX: YPB), an Australian based product verification and customer engagement company. Namaste has identified the need for its global customers to have confidence in the products they are purchasing, and for vendors to have access to granular data on their end-users. As such, Namaste plans to introduce YPB’s solutions across its network of manufacturers and to Canadian Licensed Producers to bring certainty of authenticity and supply chain transparency to the entire legal cannabis industry globally. This coalition furthers Namaste’s agenda in providing leading technology platforms for its global marketplace and in enhancing the user’s experience for its customers.

Namaste is the world’s largest and most comprehensive cannabis-focused e-commerce platform with 32 sites in 20 countries and over 600,000 monthly visits to their e-commerce sites with a database of approximately 1.5 million users. Their fully integrated e-commerce network spans across the globe offering everything from rolling papers to vaporizers. In Canada, Namaste has developed the country’s first telemedicine app, available on iPhone and Android devices which allows patients to connect to doctors or nurse practitioners and have access to a wide range of high-quality cannabis products and services. The shared strategy of this Agreement is to leverage Namaste’s market position with the objective that all vendors on its platform across the entire cannabis supply chain will adopt this technology and mark every product with YPB ProtectCodes to help protect consumers by ensuring the products and services they are purchasing are safe and reliable.

Sean Dollinger, President, and CEO of Namaste comments: “Our extensive tender process identified Australian-based company YPB as being able to deliver the most sophisticated forensic level anti-counterfeit security for brand protection. We are confident YPB’s Secure Supply Chain tracking will enhance trust in the legitimacy and integrity of the vast range of products and services being sold throughout the industry. Namaste has spent years building strong, trusted relationships with vendors in the industry many of whom suffer from having their products counterfeited and sold through unlicensed distributors. Through this partnership, Namaste offers an effective solution to further support our vaporizer and hardware vendors. Additionally, we believe this technology has the ability to revolutionize the sale of cannabis throughout the Canadian market, with the potential for global market penetration. We fully intend on leveraging our relationships with licensed producers with the hope of providing additional value to LP’s and their customers. As the market expands and becomes more competitive we expect to see an increased demand for the adoption and implementation of anti-counterfeit security to ensure all parties involved are adequately protected. We believe YPB is a leader in the space and we are excited to work alongside them to come up with unique solutions for the cannabis industry.

In the last five years, Founder and CEO of YPB, John Houston has seen a notable increase in the number of global eCommerce brands who are looking at how to protect consumers and brand value with YPB’s technology. It is predicted that by 2022, the value of the global counterfeit market will reach $US4.2 Trillion and 5.4 million jobs will be at risk. According to World Health Organization estimates, one million people die each year from counterfeit medicines. Counterfeit is a global issue and brands are increasingly needing to become smarter and look at ways to protect their customers from fakes to mitigate risk to their brand reputation.

The ability to engage directly with customers who have scanned a YPB protected product to confirm authenticity but have not purchased through a Namaste platform will also provide them with valuable market intelligence to know, understand and connect with a greater proportion of the cannabis community more effectively.

John Houston, YPB Executive Chairman comments: “Namaste is a smart, rapidly growing company with powerful competitive advantages and a unique central hub position in the legal cannabis industry. YPB could not find a better partner with whom to participate in the expected rapid growth of cannabis consumption. Namaste’s footprint offers YPB exceptional global access with ease of execution at low cost and its adoption of our technology is recognition of the power of product authenticity to build customer trust, relationships and numbers. This is YPB’s single biggest opportunity yet and we will work closely with Namaste to ensure conversion to real shareholder wealth. I’m also delighted to welcome Namaste onto our share register and the magnification of our mutual interests that it brings.”

ABOUT NAMSTE TECHNOLOGIES

Namaste Technologies is a global leader in the sale of medical cannabis consumption devices. Namaste has nine offices with multiple distribution centers around the globe and operates over 30 websites under various brands. Namaste has developed innovative technology platforms including NamasteMD.com, Canada’s first ACMPR compliant telemedicine application. The company is focused on patient acquisition through NamasteMD and intends on building Canada’s largest database of medical cannabis patients. The company’s subsidiary, CannMart Inc. is an ACMPR Licensed Producer pending receipt of a “sales-only” license, whereby the company will offer a large variety of medical cannabis sourced from domestic and international producers. Namaste will continue to develop and acquire innovative technologies which will provide value to the Company and to its shareholders as well as to the broader cannabis market.

About YPB

Established in Australia in 2011 (listed on the ASX in 2014), YPB is at the centre of the global fight to protect the integrity of brands from commercial losses through highly advanced authentication solutions that enable brands to trigger customer engagement.

On behalf of the Board of Directors

“Sean Dollinger”

Chief Executive Officer

Direct: +1 (786) 389 9771

Email: [email protected]

Further information on the Company and its products can be accessed through the links below:

NamasteTechnologies.com

NamasteMD.com

NamasteVapes.ca

Everyonedoesit.ca

FORWARD-LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Neither the TSX Venture Exchange nor its market regulator has reviewed or approved the contents of this press release.

SOURCE Namaste Technologies Inc.

View original content with multimedia: http://www.newswire.ca/en/releases/archive/June2018/27/c3887.html

Sean Dollinger, Chief Executive Officer, Direct: +1 (786) 389 9771, Email: [email protected] CNW Group 2018